Earnings Report /

Rameda Pharmaceuticals: Private sales recovery supports performance despite UMPA challenges

  • Modest growth in retail pharma market caps performance

  • New launches and Covid related antivirals drive topline growth

  • Profitability improved on the back of a decline in antivirals’ APIs costs

Mariam Wael
Al Ahly Pharos Securities Brokerage
9 August 2021